Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A clinical deep-dive into sirolimus pharmacokinetics, wound healing risks, mTOR-mediated metabolic effects, and dosing considerations specific to post-bariatric surgery patients.
Read clinical reviewA clinical deep-dive into how rapamycin (sirolimus) affects sleep architecture, circadian biology, mTOR signaling in the brain, and what the PEARL trial and related primary literature reveal for patients and prescribers.
Read clinical reviewA clinician-level review of how rapamycin (sirolimus) affects appetite, hunger signaling, and food cravings, covering transplant doses, low-dose longevity protocols, mTOR biology, and the PEARL trial data.
Read clinical reviewA physician-reviewed, evidence-based guide to how sirolimus affects autoimmune disease, mechanisms, clinical evidence, dosing considerations, and risks, for clinicians and informed patients.
Read clinical reviewA physician-reviewed, primary-literature analysis of how rapamycin (sirolimus) affects bone mineral density, osteoblast and osteoclast signaling, fracture risk, and clinical management strategies for transplant and longevity patients.
Read clinical reviewA physician-level review of the cancer risk data for rapamycin (sirolimus), covering transplant cohorts, mTOR biology, animal data, and what the PEARL trial tells us about off-label longevity use.
Read clinical reviewA physician-level review of rapamycin (sirolimus) cardiovascular effects over time, covering atherosclerosis, dyslipidemia, hypertension, cardiac aging, and emerging longevity trial data including PEARL 2024.
Read clinical reviewA physician-reviewed deep dive into how rapamycin (sirolimus) affects cognition in humans and animals, covering mTOR biology, clinical trial data including PEARL (2024), dosing, and safety considerations for off-label longevity use.
Read clinical reviewA physician-reviewed comparison of compounded sirolimus versus branded Rapamune, covering bioavailability, regulatory status, dosing for off-label longevity use, and what the PEARL trial data show.
Read clinical reviewA GRADE-level review of every major sirolimus trial and guideline, from FDA-approved transplant indications to off-label longevity use. Includes PEARL (2024), TRITON, and the 2021 KDIGO transplant guidelines.
Read clinical reviewA comprehensive clinical review of sirolimus-related dermatologic effects, including acneiform eruptions, hair loss, impaired wound healing, and emerging longevity-dose data, with primary-literature citations throughout.
Read clinical reviewA physician-reviewed deep dive into how rapamycin (sirolimus) affects liver function, including hepatotoxicity risk, transaminase changes, lipid effects, and monitoring protocols backed by primary literature.
Read clinical reviewA clinician-level review of how rapamycin (sirolimus) affects mood, cognition, anxiety, and depression, covering mTOR neuroscience, PEARL trial data, and practical prescribing guidance.
Read clinical reviewA clinical deep-dive into how rapamycin (sirolimus) alters mTOR signaling, mitochondrial function, glucose metabolism, and energy expenditure, with primary-literature citations for physicians and informed patients.
Read clinical reviewA clinician-level review of rapamycin microdosing protocols for longevity, covering PEARL and other primary trials, dosing regimens, pharmacology, safety data, and what board-certified physicians consider before prescribing off-label sirolimus.
Read clinical reviewBoard-reviewed clinical guide to rapamycin (sirolimus) muscle preservation strategies, covering mTORC1/mTORC2 biology, optimal dosing schedules, resistance training protocols, and nutritional co-interventions backed by primary literature.
Read clinical reviewWhy your rapamycin dose has stopped working and what to do about it: a clinician-level guide to sirolimus plateau, non-response, biomarker drift, and protocol adjustments backed by primary literature.
Read clinical reviewA physician-level guide to the sirolimus pre-surgery hold window: how long to stop rapamycin before an operation, why wound healing and immune suppression demand a specific washout period, and how to restart safely after surgery.
Read clinical reviewA physician-level review of what happens when you stop rapamycin (sirolimus): mTOR rebound kinetics, immune reconstitution, clinical data from transplant and longevity contexts, and evidence-based tapering strategies.
Read clinical reviewA clinician-level guide to adjusting sirolimus dosing, lab monitoring, and infection precautions by season, with primary-literature citations and a practical seasonal framework.
Read clinical reviewA physician-reviewed deep dive into how rapamycin (sirolimus) affects sexual function in men and women, covering mTOR biology, clinical trial data, dose-dependent effects, and practical management strategies.
Read clinical reviewMD/PharmD-level guidance on dosing sirolimus across time zones, managing refrigeration, avoiding grapefruit and CYP3A4 interactions on the road, and what the PEARL trial data means for longevity travelers.
Read clinical reviewA week-by-week clinical guide to the first month on rapamycin (sirolimus) for longevity use, covering pharmacokinetics, expected effects, common side effects, dosing schedules, and monitoring protocols backed by primary literature.
Read clinical reviewA physician-reviewed deep dive into sirolimus and kidney health: when mTOR inhibition protects the kidney, when it harms it, and what the latest trials including PEARL 2024 say about safe dosing.
Read clinical reviewA physician-level guide to safely restarting sirolimus after acute illness, covering hold durations, immune recovery markers, dose re-escalation protocols, and the latest evidence from PEARL (2024) and transplant guidelines.
Read clinical review